All In Biotech

Drug Trial Radar · NCT05330884

BCG Revaccination in Children and Adolescents

Efficacy of BCG Revaccination Compared With Oral Chemoprophylaxis in Household Contacts Aged 6-18 Years for Prevention of Tuberculosis Disease - A Phase III Open Labelled Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 9,200 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

9,200

Planned (sponsor's estimate)

Start

Jul 15, 2024

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Tuberculosis Research Centre, IndiaGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Institute of Child Health, Chennai; All India Institute of Medical Sciences; The Grant Medical College & Sir J.J. Group of Hospitals; All India Institute of Medical Sciences, Bhubaneswar; Rajendra Institute of Medical Sciences, Ranchi; National Institute of Tuberculosis and Respiratory Diseases, New Delhi; Rajiv Gandhi Hospital, Chennai; Madurai Medical College; Government Vellore Medical College, Vellore
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection. The efficacy of BCG vaccination in newborns is well known and has a documented protective effect against meningitis and disseminated TB in children. However, there is considerable uncertainty on BCG revaccination. It is known that BCG revaccination enhances immune responses, but it is yet to be established if BCG revaccination can help prevent TB disease in household contacts. The primary aim of this study is to assess the efficacy of BCG revaccination compared to oral chemoprophylaxis in preventing TB disease in house hold contacts aged 6-18 years. The study is designed as a multicentre randomised controlled trial with two groups of healthy household contacts aged 6-18 years receiving either the BCG vaccine or oral chemoprophylaxis. They will be followed up for 24 months to compare the incidence of TB disease in each arm.

Conditions

  • Tuberculosis Infection
  • Tuberculosis

Interventions

  • BCG vaccineBiological

    0.1ml BCg vaccine to be given intradermally

  • Oral ChemoprophylaxisDrug

    Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TB (all forms - PTB / EPTB) as per NTEP guidelinesTime frame: over 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr Aishwarya Venkataraman

    Chennai, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.